CN110958885B - 多肽化合物在治疗急性胰腺炎中的应用 - Google Patents
多肽化合物在治疗急性胰腺炎中的应用 Download PDFInfo
- Publication number
- CN110958885B CN110958885B CN201780090649.9A CN201780090649A CN110958885B CN 110958885 B CN110958885 B CN 110958885B CN 201780090649 A CN201780090649 A CN 201780090649A CN 110958885 B CN110958885 B CN 110958885B
- Authority
- CN
- China
- Prior art keywords
- peptide
- acid
- seq
- acute pancreatitis
- ingap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 125
- 206010033645 Pancreatitis Diseases 0.000 title claims abstract description 63
- 206010033647 Pancreatitis acute Diseases 0.000 title claims abstract description 54
- 201000003229 acute pancreatitis Diseases 0.000 title claims abstract description 54
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 13
- 150000001875 compounds Chemical class 0.000 title abstract description 8
- 229920001184 polypeptide Polymers 0.000 title abstract description 5
- 239000004367 Lipase Substances 0.000 claims abstract description 15
- 102000004882 Lipase Human genes 0.000 claims abstract description 15
- 108090001060 Lipase Proteins 0.000 claims abstract description 15
- 210000004369 blood Anatomy 0.000 claims abstract description 15
- 239000008280 blood Substances 0.000 claims abstract description 15
- 235000019421 lipase Nutrition 0.000 claims abstract description 15
- 239000004382 Amylase Substances 0.000 claims abstract description 14
- 102000013142 Amylases Human genes 0.000 claims abstract description 14
- 108010065511 Amylases Proteins 0.000 claims abstract description 14
- 235000019418 amylase Nutrition 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 229940079593 drug Drugs 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- WMUIYURBHSELFV-NZODMTSUSA-N (3s)-4-[(2s)-2-[[(2s)-1-[[(2s)-1-[[2-[[(2s,3r)-1-[[(2s)-1-[(2s)-2-[[(2s)-4-amino-1-[[2-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-2-oxoethyl]amino]-1,4-dioxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O)C1=CN=CN1 WMUIYURBHSELFV-NZODMTSUSA-N 0.000 abstract description 54
- 210000000496 pancreas Anatomy 0.000 abstract description 13
- 230000001575 pathological effect Effects 0.000 abstract description 5
- 230000006378 damage Effects 0.000 abstract description 3
- 230000034994 death Effects 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- 238000010171 animal model Methods 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 12
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 11
- 206010030113 Oedema Diseases 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 229960002989 glutamic acid Drugs 0.000 description 10
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 9
- 235000013922 glutamic acid Nutrition 0.000 description 9
- 239000004220 glutamic acid Substances 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 8
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 8
- 235000018417 cysteine Nutrition 0.000 description 8
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000002504 physiological saline solution Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- 150000003839 salts Chemical group 0.000 description 7
- 102000013585 Bombesin Human genes 0.000 description 6
- 108010051479 Bombesin Proteins 0.000 description 6
- AGPKZVBTJJNPAG-RFZPGFLSSA-N D-Isoleucine Chemical compound CC[C@@H](C)[C@@H](N)C(O)=O AGPKZVBTJJNPAG-RFZPGFLSSA-N 0.000 description 6
- 229930182845 D-isoleucine Natural products 0.000 description 6
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 6
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 6
- 229960000310 isoleucine Drugs 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 206010028851 Necrosis Diseases 0.000 description 5
- 206010033627 Pancreatic injury Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 229960003767 alanine Drugs 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- -1 alpha-Amino-isobutyl Chemical group 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 231100000915 pathological change Toxicity 0.000 description 5
- 230000036285 pathological change Effects 0.000 description 5
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 229960005261 aspartic acid Drugs 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- GDFAOVXKHJXLEI-UHFFFAOYSA-N L-N-Boc-N-methylalanine Natural products CNC(C)C(O)=O GDFAOVXKHJXLEI-UHFFFAOYSA-N 0.000 description 3
- GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 2
- QCXJEYYXVJIFCE-UHFFFAOYSA-N 4-acetamidobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1 QCXJEYYXVJIFCE-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 206010056375 Bile duct obstruction Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010008635 Cholestasis Diseases 0.000 description 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 2
- 102100022624 Glucoamylase Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000016222 Pancreatic disease Diseases 0.000 description 2
- 206010033649 Pancreatitis chronic Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010037368 Pulmonary congestion Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229950006191 gluconic acid Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000006996 mental state Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000002895 organic esters Chemical class 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 238000010827 pathological analysis Methods 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000007127 saponification reaction Methods 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- YKGYIDJEEQRWQH-UHFFFAOYSA-N 4-[6-(diaminomethylideneamino)-1-oxohexoxy]benzoic acid ethyl ester Chemical compound CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)N)C=C1 YKGYIDJEEQRWQH-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 206010061857 Fat necrosis Diseases 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 206010061974 Gastrointestinal obstruction Diseases 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010033625 Pancreatic haemorrhage Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- MIOPJNTWMNEORI-OMNKOJBGSA-N [(4s)-7,7-dimethyl-3-oxo-4-bicyclo[2.2.1]heptanyl]methanesulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-OMNKOJBGSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 229960000250 adipic acid Drugs 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- HWXBTNAVRSUOJR-UHFFFAOYSA-N alpha-hydroxyglutaric acid Natural products OC(=O)C(O)CCC(O)=O HWXBTNAVRSUOJR-UHFFFAOYSA-N 0.000 description 1
- 229940009533 alpha-ketoglutaric acid Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- KHAVLLBUVKBTBG-UHFFFAOYSA-N caproleic acid Natural products OC(=O)CCCCCCCC=C KHAVLLBUVKBTBG-UHFFFAOYSA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 210000001953 common bile duct Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- FYZZJDABXBPMOG-UHFFFAOYSA-N ethanol;n-methylmethanamine Chemical compound CCO.CNC FYZZJDABXBPMOG-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229950000501 gabexate Drugs 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 229940033355 lauric acid Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000008383 multiple organ dysfunction Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229940074355 nitric acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 229960001476 pentoxifylline Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- SBYHFKPVCBCYGV-UHFFFAOYSA-N quinuclidine Chemical compound C1CC2CCN1CC2 SBYHFKPVCBCYGV-UHFFFAOYSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940116353 sebacic acid Drugs 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- FGCSIJPPCNCQJB-FAOVPRGRSA-M sodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;chloride Chemical compound [Na+].[Cl-].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O FGCSIJPPCNCQJB-FAOVPRGRSA-M 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229950008558 ulinastatin Drugs 0.000 description 1
- 229960002703 undecylenic acid Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 108010088854 urinastatin Proteins 0.000 description 1
- ODVKSTFPQDVPJZ-UHFFFAOYSA-N urinastatin Chemical compound C1C=CCCC11COC(C=2OC=CC=2)OC1 ODVKSTFPQDVPJZ-UHFFFAOYSA-N 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical compound [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
- 229940007718 zinc hydroxide Drugs 0.000 description 1
- 229910021511 zinc hydroxide Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4733—Acute pancreatitis-associated protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
INGAP‑PP肽、HIP肽、或其类似物在制备用于治疗急性胰腺炎的药物中的用途,所述多肽化合物能显著降低急性胰腺炎导致的血液淀粉酶和脂肪酶水平的升高,减轻胰腺炎导致的胰腺病理损伤程度,并显著降低急性胰腺炎导致的死亡。
Description
技术领域
本申请涉及多肽化合物在治疗急性胰腺炎中的应用,具体的讲,涉及INGAP-PP肽、HIP肽、或其类似物在治疗急性胰腺炎中的应用。
背景技术
胰腺炎通常被认为是胰腺因胰蛋白酶的自身消化作用而引起的疾病。根据病程,胰腺炎可被分为急性胰腺炎(AP)和慢性胰腺炎(CP)两种。据报道,胰腺炎的年发病率为13-45/10万,而且,在过去30年中,急性胰腺炎发病率呈逐渐上升的趋势。
急性胰腺炎是由多种因素参与的引起全身多器官功能障碍的疾病,其典型症状包括剧烈、持续的上腹部疼痛,通常疼痛向背部和肋部放射,且常常伴有呕吐、腹胀、发热、心率增快、白细胞计数上升、血或尿淀粉酶升高。病变程度不等,从显微镜下所见的间质水肿和脂肪坏死,到肉眼可见的胰腺实质或胰周坏死和出血。急性胰腺炎的发病原因及发病机制多种多样,各种病因及机制可能相互作用,导致患者临床预后差。
目前现有的治疗手段仅限于缓解疼痛、补液以维持水和电解质平衡、营养支持、预防感染以及预防并发症等支持性保守治疗,尚没有针对急性胰腺炎的疗效显著的治疗药物。
因此,仍然需要开发能够有效治疗急性胰腺炎的新药物和方法。
发明内容
国内外关于急性胰腺炎的诊断标准基本一致,认为确诊急性胰腺炎至少须要符合以下3项标准中的2项:(1)与急性胰腺炎相一致的腹痛症状;(2)血清淀粉酶和/或脂肪酶≥3倍正常值上限;(3)符合急性胰腺炎的影像学特征。
本申请人意外的发现,INGAP-PP肽、HIP肽、或其类似物能够显著降低胰腺炎导致的血液淀粉酶和脂肪酶水平的升高,减轻胰腺炎导致的胰腺病理损伤程度,并显著提高牛黄胆酸钠诱导的急性胰腺炎模型动物的存活率。
因此,在一些方面,本申请提供了INGAP-PP肽、HIP肽、或其类似物在治疗急性胰腺炎中的应用。
在另一些方面,本申请还提供了一种治疗患者急性胰腺炎的方法,包括给予患者包含INGAP-PP肽、HIP肽或其类似物的组合物。
根据本公开的以下描述并结合附图,本公开的这些和其他方面、特征和优点将变得显而易见。
附图说明
结合附图,从以下描述来看,本公开的上述和其他特点、方面和优点将容易的理解,其中:
图1比较了急性胰腺炎动物模型中,给药组和对照组的动物存活率。
图2比较了急性胰腺炎动物模型中,给药组和对照组的血淀粉酶水平。
图3比较了急性胰腺炎动物模型中,给药组和对照组的血脂肪酶水平。
图4比较了急性胰腺炎动物模型中,给药组和对照组的胰腺水肿病理评分结果。
图5比较了急性胰腺炎动物模型中,给药组和对照组的胰腺炎症病理评分结果。
图6比较了急性胰腺炎动物模型中,给药组和对照组的胰腺出血病理评分结果。
图7比较了急性胰腺炎动物模型中,给药组和对照组的胰腺腺泡坏死病理评分结果。
图8比较了急性胰腺炎动物模型中,给药组和对照组的胰腺总损伤病理评分结果。
图9比较了急性胰腺炎动物模型中,给药组和对照组的胰腺系数结果。
图10比较了急性胰腺炎动物模型中,给药组和对照组的血淀粉酶水平。
图11比较了急性胰腺炎动物模型中,给药组和对照组的血脂肪酶水平。
图12比较了急性胰腺炎动物模型中,给药组和对照组的胰腺水肿病理评分结果。
图13比较了急性胰腺炎动物模型中,给药组和对照组的胰腺炎症病理评分结果。
具体实施方式
以下提供的每一个实施方案均有助于本公开某些方面的解释,但是不应解释为限制本公开的范围。另外,在整个说明书和权利要求书中,如本文中使用,近似的语言可应用于修饰任何数量表示,该数量表示可允许变化,而不会导致与其相关的基本功能的改变。因此,由一个术语或多个术语例如“约”修饰的值不限于指定的精确值。在一些情况,近似的语言可对应于用于测量数值的仪器的精密度。
短语“非肠道给予”和“肠胃外给予”为本领域熟知的术语,包括除肠内和局部给予以外的给予模式,例如注射,并且非限制性地包括静脉内、肌内、胸膜内、血管内、心包内、动脉内、鞘内、囊内、眶内、心脏内、真皮内、腹膜内、经气管、皮下、表皮下、关节内、被膜下、蛛网膜下、脊柱内和胸骨内注射和输注。
术语“治疗”包括在可能易患疾病、障碍和/或病症但是尚未诊断为患有的动物中防止疾病、障碍或病症的发生;抑制疾病、障碍或病症,例如阻碍其发展;和缓解疾病、障碍或病症,例如导致疾病、障碍和/或病症的消退。治疗疾病或病症包括改善具体疾病或病症的至少一个症状。
短语“药学上可接受的”指的是处于合理的医疗判断范围内,适用于与人和动物的组织接触而没有过度的毒性、刺激、变态反应或者其它问题或并发症的组合物、聚合物及其它材料和/或剂型。
短语“药学上可接受的载体”指的是参与从一个器官或身体的部分运载或运输任何受试组合物至另一个器官或身体的部分的药学上可接受的材料、组合物或媒介物,比如液体或固体填充剂、稀释剂、溶剂或包封材料。每一种载体在与受试组合物的其它成分相容并且不伤害患者的意义上必须是“可接受的”。
如本文使用,术语“患者”是指哺乳动物,如小鼠、豚鼠、大鼠、狗或人,优选患者为人。
在本申请人之前提交的PCT申请PCT/CN2014/073483和PCT/CN2013/072771中公开了INGAP-PP和HIP肽类似物及其制备,其中表明INGAP-PP肽、HIP肽、其类似物具有多种药理学活性,但是没有提及抗急性胰腺炎活性。PCT/CN2014/073483和PCT/CN2013/072771两者均通过引用而整体结合至本文中。
本申请人意外的发现,在蛙皮素诱导的小鼠急性胰腺炎模型中,INGAP-PP肽、HIP肽、其类似物(在实施例中采用序列Ac-IGLHD PSHGT LPAGS-OH,即下表2中的序列12)能够降低蛙皮素对胰腺造成的水肿和炎症等病理损伤改变,显著降低动物的血淀粉酶和脂肪酶水平(见图10和图11),在牛黄胆酸钠诱导的大鼠急性胰腺炎模型中,INGAP-PP肽、HIP肽、其类似物(在实施例中采用序列Ac-IGLHD PSHGT LPAGS-OH,即下表2中的序列12)能够显著提高动物的存活率。而且,INGAP-PP肽、HIP肽、其类似物的适用性很大,在实施例1中实验了三个剂量,分别为低剂量0.05mg/kg、中剂量0.25mg/kg和高剂量1.25mg/kg,所有给药组中存活动物均保持良好的精神状态和活动状态,显著优于对照组。
因此,本申请在一个方面提供了INGAP-PP肽、HIP肽或其类似物在治疗患者急性胰腺炎中的应用。相应的,本申请还提供了INGAP-PP肽、HIP肽或其类似物在制备用于治疗患者急性胰腺炎的药物中的用途。在一个实施方案中,所述INGAP-PP肽类似物为Ac-IGLHDPSHGT LPAGS-OH。
在以下表1-3中提供了INGAP-PP肽、HIP肽及其示例性类似物。
表1.INGAP-PP肽和HIP肽
肽编号/序列编号 | 序列 |
1(INGAP-PP) | H-IGLHDPSHGTLPNGS-OH |
2(HIP) | H-IGLHDPTQGTEPNGE-OH |
表2.示例性INGAP-PP肽类似物
表3.示例性HIP肽类似物
如本领域技术人员所公知的,在肽序列中,各符号及其所代表的氨基酸如表4所示:
表4
在一个实施方案中,所述INGAP-PP肽类似物具有如下通式:X1GLHX2PX3X4GTX5PX6GS(1);
其中,X1选自异亮氨酸(I)、D-异亮氨酸、L-正缬氨酸或L-正亮氨酸;X2选自丙氨酸(A)或天冬氨酸(D);X3选自丝氨酸(S)或苏氨酸(T);X4选自组氨酸(H)或谷氨酰胺(Q);X5选自亮氨酸(L)或谷氨酸(E);
并且,当X1为异亮氨酸(I)、X2为天冬氨酸(D)、X3为丝氨酸(S)、X4为组氨酸(H)、X5为亮氨酸(L)成立时,X6选自丙氨酸(A)、α-氨基异丁酸或N-甲基-L-丙氨酸;
当X1为异亮氨酸(I)、X2为天冬氨酸(D)、X3为丝氨酸(S)、X4为组氨酸(H)、X5为亮氨酸(L)不成立时,X6选自丙氨酸(A)、天冬酰胺(N)、α-氨基异丁酸或N-甲基-L-丙氨酸。
在一个具体的实施方案中,通式(1)的INGAP-PP肽类似物可选自:
H-IGLHAPSHGTLPNGS-OH(序列编号:6)、
H-IGLHDPSHGTLP(Aib)GS-OH(序列编号:10)、
H-IGLHDPSHGTLP(N-methyl-L-Alanine)GS-OH(序列编号:11)、
H-(D-Isoleucine)GLHDPSHGTLPNGS-OH(序列编号:17)、
H-IGLHDPSHGTEPNGS-OH(序列编号:18)、
H-IGLHDPSQGTLPNGS-OH(序列编号:19)、和
H-IGLHDPTHGTLPNGS-OH(序列编号:20)。
在另一个具体的实施方案中,通式(1)的INGAP-PP肽类似物可选自:
H-IGLHDPSHGTLPAGS-OH(序列编号:7)、
H-IGLHAPSHGTLPAGS-OH(序列编号:8)、
H-(D-Isoleucine)GLHDPSHGTLPAGS-OH(序列编号:13)、
H-(L-NorValine)GLHDPSHGTLPAGS-OH(序列编号:14)、
H-(L-NorLeucine)GLHDPSHGTLPAGS-OH(序列编号:15)、
H-IGLHDPSHGTEPAGS-OH(序列编号:24)、
H-IGLHDPSQGTLPAGS-OH(序列编号:25)、和
H-IGLHDPTHGTLPAGS-OH(序列编号:26)。
在一个实施方案中,所述INGAP-PP肽类似物具有如下通式:R1-IGLHDPSHGTLPNGX1(C)m-R2 (2);
其中,m为0或1;R1选自-H或-Ac;R2选自-OH或-NH2;
并且,当R1为-H、R2为-OH且m为0成立时,X1选自谷氨酸(E)、半胱氨酸(C)或赖氨酸(K);
当R1为-H、R2为-OH且m为0不成立时,X1选自丝氨酸(S)、谷氨酸(E)、半胱氨酸(C)或赖氨酸(K)。
在一个具体的实施方案中,通式(2)的INGAP-PP肽类似物可选自:H-IGLHDPSHGTLPNGE-OH(序列编号:21)和H-IGLHDPSHGTLPNGK-OH(序列编号:22)。
在一个具体的实施方案中,通式(2)的INGAP-PP肽类似物可选自:
Ac-IGLHDPSHGTLPNGS-NH2(序列编号:31)、
H-IGLHDPSHGTLPNGS-NH2(序列编号:32)、和
Ac-IGLHDPSHGTLPNGS-OH(序列编号:16)。
在一个具体的实施方案中,通式(2)的INGAP-PP肽类似物可选自:
H-IGLHDPSHGTLPNGC-OH(序列编号:37)、
Ac-IGLHDPSHGTLPNGC-OH(序列编号:38)、
H-IGLHDPSHGTLPNGC-NH2(序列编号:39)、和
Ac-IGLHDPSHGTLPNGC-NH2(序列编号:40)。
在一个具体的实施方案中,通式(2)的INGAP-PP肽类似物可选自:
H-IGLHDPSHGTLPNGSC-OH(序列编号:33)、
Ac-IGLHDPSHGTLPNGSC-OH(序列编号:34)、
H-IGLHDPSHGTLPNGSC-NH2(序列编号:35)、和
Ac-IGLHDPSHGTLPNGSC-NH2(序列编号:36)。
在一个具体的实施方案中,通式(2)的INGAP-PP肽类似物可选自:
H-IGLHDPSHGTLPNG-OH(序列编号:74)、
Ac-IGLHDPSHGTLPNG-OH(序列编号:75)、
H-IGLHDPSHGTLPNG-NH2(序列编号:76)、和
Ac-IGLHDPSHGTLPNG-NH2(序列编号:77)。
在一个实施方案中,所述INGAP-PP肽类似物具有如下通式:
R1-IGLHDPSHGTLPAG(X1)m-R2 (3);
其中,m为0或1;R1选自-H或-Ac;R2选自-OH或-NH2;
当R1为-H、R2为-OH且m为1成立时,X1选自谷氨酸(E)、半胱氨酸(C)或赖氨酸(K);
当R1为-H、R2为-OH且m为1不成立时,X1选自丝氨酸(S)、谷氨酸(E)、半胱氨酸(C)或赖氨酸(K)。
在一个具体的实施方案中,通式(3)的INGAP-PP肽类似物可选自:H-IGLHDPSHGTLPAGE-OH(序列编号:27)和H-IGLHDPSHGTLPAGK-OH(序列编号:23)。
在一个具体的实施方案中,通式(3)的INGAP-PP肽类似物可选自:Ac-IGLHDPSHGTLPAGS-NH2(序列编号:29)、
H-IGLHDPSHGTLPAGS-NH2(序列编号:41)、和
Ac-IGLHDPSHGTLPAGS-OH(序列编号:12)。
在一个具体的实施方案中,通式(3)的INGAP-PP肽类似物可选自:
H-IGLHDPSHGTLPAGC-OH(序列编号:46)、
Ac-IGLHDPSHGTLPAGC-OH(序列编号:47)、
H-IGLHDPSHGTLPAGC-NH2(序列编号:48)、和
Ac-IGLHDPSHGTLPAGC-NH2(序列编号:49)。
在一个具体的实施方案中,通式(3)的INGAP-PP肽类似物可选自:
H-IGLHDPSHGTLPAG-OH(序列编号:73)、
H-IGLHDPSHGTLPAG-NH2(序列编号:28)、和
Ac-IGLHDPSHGTLPAG-NH2(序列编号:30)。
在一个实施方案中,所述INGAP-PP肽类似物具有如下通式:
R1-IGLHDPSHGTLPAGSX2-R2 (4);
其中,X2选自赖氨酸(K)或半胱氨酸(C),R1选自-H或-Ac,R2选自-OH或-NH2。
在一个具体的实施方案中,通式(4)的INGAP-PP肽类似物可选自:
H-IGLHDPSHGTLPAGSK-OH(序列编号:9)、
H-IGLHDPSHGTLPAGSC-OH(序列编号:42)、
Ac-IGLHDPSHGTLPAGSC-OH(序列编号:43)、
H-IGLHDPSHGTLPAGSC-NH2(序列编号:44)、和
Ac-IGLHDPSHGTLPAGSC-NH2(序列编号:45)。
在一个实施方案中,所述HIP肽类似物具有如下通式:
X1GLHDPTQGTX2PX3GE (5);
X1选自异亮氨酸(I)或D-异亮氨酸;X2选自谷氨酸(E)或亮氨酸(L);
并且,当X1为异亮氨酸(I)且X2为谷氨酸(E)成立时,X3选自丙氨酸(A)或α-Amino-isobutyric acid;
当X1为异亮氨酸(I)且X2为谷氨酸(E)不成立时,X3选自丙氨酸(A)、天冬酰胺(N)或α-氨基异丁酸。
在一个具体的实施方案中,通式(5)的HIP肽类似物可选自:
H-IGLHDPTQGTEP(Aib)GE-OH(序列编号:51)、
H-(D-Isoleucine)GLHDPTQGTEPNGE-OH(序列编号:55)、和
H-IGLHDPTQGTLPNGE-OH(序列编号:58)。
在一个具体的实施方案中,通式(5)的HIP肽类似物可选自:
H-IGLHDPTQGTEPAGE-OH(序列编号:50)、
H-(D-Isoleucine)GLHDPTQGTEPAGE-OH(序列编号:53)、和
H-IGLHDPTQGTLPAGE-OH(序列编号:59)。
在一个实施方案中,所述HIP肽类似物具有如下通式:R1-IGLHDPTQGTEPNGX1-R2 (6);
其中,R1选自-H或-Ac;R2选自-OH或-NH2;
当R1为-H且R2为-OH成立时,X1选自丝氨酸(S)或半胱氨酸(C);
当R1为-H且R2为-OH不成立时,X1选自丝氨酸(S)、谷氨酸(E)或半胱氨酸(C)。
在一个具体的实施方案中,通式(6)的HIP肽类似物可选自:
Ac-IGLHDPTQGTEPNGE-OH(序列编号:54)、
Ac-IGLHDPTQGTEPNGE-NH2(序列编号:61)、和
H-IGLHDPTQGTEPNGE-NH2(序列编号:63)。
在一个具体的实施方案中,通式(6)的HIP肽类似物可选自:
H-IGLHDPTQGTEPNGS-OH(序列编号:56)、
H-IGLHDPTQGTEPNGC-OH(序列编号:64)、
Ac-IGLHDPTQGTEPNGC-OH(序列编号:65)、
H-IGLHDPTQGTEPNGC-NH2(序列编号:66)、和
Ac-IGLHDPTQGTEPNGC-NH2(序列编号:67)。
在一个实施方案中,所述HIP肽类似物具有如下通式:R1-IGLHDPTQGTEPAG(X1)n-R2 (7);
其中,R1选自-H或-Ac;R2选自-OH或-NH2;n为0或1;X1选自丝氨酸(S)或半胱氨酸(C)。
在一个具体的实施方案中,通式(7)的HIP肽类似物可选自:
H-IGLHDPTQGTEPAGS-OH(序列编号:57)、
Ac-IGLHDPTQGTEPAG-NH2(序列编号:60)、
H-IGLHDPTQGTEPAGC-OH(序列编号:69)、
Ac-IGLHDPTQGTEPAGC-OH(序列编号:70)、
H-IGLHDPTQGTEPAGC-NH2(序列编号:71)、和
Ac-IGLHDPTQGTEPAGC-NH2(序列编号:72)。
在一个具体的实施方案中,通式(7)的HIP肽类似物可选自:
Ac-IGLHDPTQGTEPAGE-OH(序列编号:52)、
Ac-IGLHDPTQGTEPAGE-NH2(序列编号:62)、和
H-IGLHDPTQGTEPAGE-NH2(序列编号:68)。
用于本发明的INGAP-PP肽、HIP肽、或其类似物可以任何药学上可接受的盐形式存在。尤其有用的盐形式是醋酸盐和盐酸盐。当用于本发明的INGAP-PP肽、HIP肽、或其类似物含有酸性部分或碱性部分时,其可以药学上可接受的盐形式提供(例如参见Berge et al.,J.Pharm.Sci.1977,66,1-19;and Handbook of Pharmaceutical Salts,Properties,andUse;Stahl and Wermuth,Ed.;Wiley-VCH and VHCA:Zurich,Switzerland,2002)。
用于制备药学上可接受的盐的适合的酸包括但不限于:醋酸、2,2-二氯醋酸、酰化氨基酸、己二酸、藻酸、抗坏血酸、L-天冬氨酸、苯磺酸、苯甲酸、4-乙酰氨基苯甲酸、硼酸、(+)-樟脑酸、樟脑磺酸、(+)-(1S)-樟脑-10-磺酸、癸酸、正己酸、辛酸、肉桂酸、柠檬酸、环拉酸、环己基氨基磺酸、十二烷基硫酸、1,2-乙二磺酸、乙磺酸、2-羟乙基磺酸、甲酸、富马酸、半乳糖二酸、龙胆酸、葡庚糖酸、D-葡萄糖酸、D-葡萄糖醛酸、L-谷氨酸、α-酮戊二酸、甘醇酸、马尿素、氢溴酸、盐酸、氢碘酸、(+)-L-乳酸、(±)-DL-乳酸、乳糖酸、月桂酸、马来酸、(-)-L-苹果酸、丙二酸、(±)-DL-苦杏仁酸、甲磺酸、2-萘磺酸、1,5-萘二磺酸、1-羟基-2-萘甲酸、烟酸、硝酸、油酸、乳清酸、草酸、棕榈酸、扑酸、高氯酸、磷酸、L-焦谷氨酸、葡糖二酸、水杨酸、4-氨基水杨酸、癸二酸、硬脂酸、琥珀酸、硫酸、鞣酸、L-酒石酸、硫氰酸、对甲苯磺酸、十一烯酸和戊酸。
用于制备药学上可接受的盐的适合的碱包括但不限于:无机碱,如氢氧化镁、氢氧化钙、氢氧化钾、氢氧化锌、或氢氧化钠;和有机碱,如伯、仲、叔、和丁、脂肪族和芳香族胺,包括:L-精氨酸、苯乙苄胺、二苄乙二胺、胆碱、二甲胺乙醇、二乙醇胺、二乙胺、二甲胺、丙胺、二异丙胺、二乙氨基乙醇、乙醇胺、乙胺、乙二胺、异丙胺、葡甲胺、海巴明、1H-咪唑、L-赖氨酸、吗啡林、4-(2-羟乙基)吗啉、甲胺、哌啶、哌嗪、丙胺、吡咯烷、1-(2-羟乙基)吡咯烷、吡啶、奎宁环、喹啉、异喹啉、仲胺、三乙醇胺、三甲胺、三乙胺、N-甲基-D-葡萄糖胺、三羟甲基氨基甲烷、和氨丁三醇。
用于本发明的INGAP-PP肽、HIP肽、或其类似物可与药学上可接受的载体组合,配制成组合物,以治疗患者的急性胰腺炎。药学上可接受的载体可为:例如,水、磷酸钠缓冲液、磷酸缓冲盐溶液、生理盐水或林格溶液或其他生理缓冲盐水、或其他溶液或溶媒,如乙二醇、甘油、油脂如橄榄油或可注射的有机酯。
药学上可接受的载体可包括生理上可接受的化合物,例如,稳定或提高本发明使用的INGAP-PP肽、HIP肽、或其类似物的吸收的化合物。这些生理上可接受的化合物包括,如,葡萄糖、蔗糖或葡聚糖等的碳水化合物;抗坏血酸或谷胱甘肽等的抗氧剂;可破坏微生物膜的乙二胺四乙酸(EDTA)等的螯合剂;钙或镁等二价金属离子;低分子量蛋白;或其他稳定剂或辅料。本领域的技术人员应该了解根据需要选择药学上可接受的载体,包括生理上可接受的化合物,例如,依据组合物的给药途径进行选择。适合的载体和它们的配方是本领域的技术人员所熟知的(例如参见Remington:The Science and Practice of Pharmacy,19th ed.,ed.A.R.Gennaro,Mack Publishing Company,Easton,PA(1995);andRemington’s Pharmaceutical Sciences,18th ed.,Mack Publishing Company,EastonPA(1990))。经典的比如,适量的药学上可接受的盐用在配方中调节制剂的等渗性。溶液的pH一般在5-8,比如7-7.5。
药学上可接受的载体是本领域的技术人员所熟知的。其中最经典的是人用药的标准载体,包括如无菌水、生理盐水和上述的生理pH的缓冲溶液等的溶液。药用组合物可包括载体、增稠剂、稀释剂、缓冲液、防腐剂、表面活性剂、和增加所述INGAP-PP肽、HIP肽、或其类似物分子选择可能性的物质。
其他的载体可包括缓释或控释制剂用载体,比如与所述INGAP-PP肽、HIP肽、或其类似物以共价或非共价结合的固体疏水聚合物的半透基质,这些基质以成型制品的形式使用,如膜、脂质体、非脂质体的脂质复合物或微粒体等类似材料,或其它本领域技术人员熟知的生物相容性聚合物(例如参见U.S.Patent No.6,824,822和8,329,648)。由磷脂或其他脂类形成的脂质体是无毒的、生理上可接受和降解的,且制备和服用都相对简单(Gregoriadis,Liposome Technology,Vol.1(CRC Press,Boca Raton Fla.,1984)。各种给药方式是本领域技术人员所熟知的(Langer,Nature 392(Suppl):5-10(1998);Langer etal.,Nature 428:487-492(2004))。依据情况特定的载体,这对本领域的技术人员是显而易见的,比如说根据给药途径和给药组成的浓度选择。
药用组合物根据局部或系统治疗的需要和治疗部位,可以有许多给药方式。可以理解为可以采用多种给药途径来给予所述INGAP-PP肽、HIP肽、或其类似物。这些给药途径包括系统和局部给药途径,并且包括且不限于静脉注射、腹腔注射、肌肉注射、皮下注射、透皮给药、经皮扩散或电泳、吸入给药、口服给药、局部注射、腔道给药、和缓释传输装置,包括局部植入缓释装置,如生物可降解或储蓄池式植入体。给药可以是局部的(包括眼部、阴道、直肠、鼻内)、口服的,吸入式的、非肠道的,例如静脉点滴、皮下注射、腹腔注射或肌肉注射。
非肠道给药的制剂包括无菌水溶液或非水溶液、混悬剂和乳剂。非水溶液的实例有丙二醇、聚乙二醇、橄榄油等植物油、和可注射的有机酯,如油酸乙酯。水性载体有包括生理盐水和缓冲溶媒在内的水剂、乙醇/水剂、乳剂或混悬剂。肠外溶媒包括氯化钠溶液、林格葡萄糖、葡萄糖氯化钠、林格乳酸盐,或不挥发油类。静脉注射溶媒包括流体、营养补充剂、电解质补充剂(如林格葡萄糖)等。防腐剂和其它添加剂可以为,例如抗菌剂、抗氧剂、螯合剂,和惰性气体等。胰岛素是熟知的肽类治疗药物,因此,胰岛素给药的方法特别适合用于本发明的多肽或其类似物的给药,这包括但不限于注射器、注射笔、输液泵、吸入器、口腔喷雾、片剂等。
在另一个方面,本申请提供了治疗患者急性胰腺炎的方法,包括给予患者包含INGAP-PP肽、HIP肽、或其类似物的药用组合物。在一个实施方案中,所述INGAP-PP肽类似物为Ac-IGLHD PSHGT LPAGS-OH。
在还另一个方面,本申请提供了降低急性胰腺炎患者血液淀粉酶和脂肪酶水平的方法,包括给予患者包含INGAP-PP肽、HIP肽、或其类似物的药用组合物。在一个实施方案中,所述INGAP-PP肽类似物为Ac-IGLHD PSHGT LPAGS-OH。
在还另一个方面,本申请提供了通过降低急性胰腺炎患者血液淀粉酶和脂肪酶的水平来治疗患者急性胰腺炎的方法,包括给予患者包含INGAP-PP肽、HIP肽、或其类似物的药用组合物。在一个实施方案中,所述INGAP-PP肽类似物为Ac-IGLHD PSHGT LPAGS-OH。
在还一个方面,本申请提供了一种用于防止或减少由于急性胰腺炎导致的胰腺损伤的方法,包括给予患者包含INGAP-PP肽、HIP肽、或其类似物的药用组合物。在一个实施方案中,所述INGAP-PP肽类似物为Ac-IGLHD PSHGT LPAGS-OH。
在还一个方面,本申请提供了一种用于治疗炎性胰腺疾病或病症的方法,包括给予患者包含INGAP-PP肽、HIP肽、或其类似物的药用组合物。在一个实施方案中,所述INGAP-PP肽类似物为Ac-IGLHD PSHGT LPAGS-OH。
相应的,本申请也提供了包含INGAP-PP肽、HIP肽、或其类似物的药用组合物在治疗患者急性胰腺炎中的用途。
药用组合物中所含的INGAP-PP肽、HIP肽、或其类似物的给药剂量可在宽范围内选择,包括但不限于0.0005mg/kg/天-100mg/kg/天,例如约0.0005mg/kg/天,约0.001mg/kg/天,约0.005mg/kg/天,约0.01mg/kg/天,约0.025mg/kg/天,约0.05mg/kg/天,约0.1mg/kg/天,约0.25mg/kg/天,约0.5mg/kg/天,约0.75mg/kg/天,约1.0mg/kg/天,约1.25mg/kg/天,约1.50mg/kg/天,约1.75mg/kg/天,约2.0mg/kg/天,约2.5mg/kg/天,约5.0mg/kg/天,约10.0mg/kg/天,约15.0mg/kg/天,约25.0mg/kg/天,约50.0mg/kg/天,约75.0mg/kg/天,或约100mg/kg/天,等等。示例性剂量范围包括但不限于0.0005mg/kg/天-0.005mg/kg/天,0.005mg/kg/天-0.05mg/kg/天,0.025mg/kg/天-0.25mg/kg/天,0.05mg/kg/天-0.5mg/kg/天,0.25mg/kg/天-2.5mg/kg/天,0.5mg/kg/天-5.0mg/kg/天,2.5mg/kg/天-25.0mg/kg/天,5.0mg/kg/天-50.0mg/kg/天,或25.0mg/kg/天-100mg/kg/天,等等。
本发明中所用的INGAP-PP肽、HIP肽、或其类似物还可以与其他的已知或者待开发的急性胰腺炎治疗药物组合在同一制剂中同时给予急性胰腺炎患者,也可以不同的制剂分别给予急性胰腺炎患者。可以与本申请中所用INGAP-PP肽、HIP肽、或其类似物联合施用的急性胰腺炎治疗药物包括但不限于胰酶分泌抑制药物,如胰高血糖素、降血钙素、生长抑制激素及其类似物奥曲肽等;蛋白酶抑制剂,如乌司他丁、加贝酯等;肿瘤坏死因子α(TNF-α)抑制剂,如己酮可可碱;和其他治疗急性胰腺炎的药物,如抗氧化剂、血小板激活因子拮抗剂、益生菌和活化蛋白C等。
下面的实施例意在举例说明本发明,不应以任何方式解释为限制本发明。
实施例1肽12对牛黄胆酸钠诱导的胰腺炎模型的治疗效果
Sprague-Dawley(SD)大鼠雌性60只,雄性70只适应性喂养7天以上,于造模前过夜禁食,随机选取雌性动物5只,雄性动物8只为正常对照组;随机选取雌性动物5只,雄性动物8只打开腹腔,翻十二指肠及胰腺作为假手术组。剩余动物按照35mg/kg的剂量从胆总管逆行注射给予牛磺胆酸钠溶液的方式制备急性胰腺炎模型。造模后,动物随机分成模型对照组(10mL/kg,生理盐水)、肽12低剂量组(0.05mg/kg,肽12的生理盐水溶液)、肽12中剂量组(0.25mg/kg,肽12的生理盐水溶液)和肽12高剂量组(1.25mg/kg,肽12的生理盐水溶液),每组雌、雄大鼠各12只。
造模后当天皮下注射给药一次,第二天给药一次,共连续给药2天,实验周期3天。试验期间对动物进行笼旁观察,观察内容包括动物的死亡或濒死、精神状态、行为活动、粪便性状、皮肤、被毛、眼、耳、鼻、腹部、外生殖器、肛门、四肢、足、呼吸等。试验结束时,所有存活大鼠称重并采集血液样本,检测各组大鼠血清中的淀粉酶、血钙、脂肪酶各项指标水平,解剖进行大体观察,重点对胰腺状况、胃肠状况、是否有腹水、胆管阻塞、肺淤血和皂化斑等进行观察和记录,取胰腺保存于10%福尔马林固定液留待进行后续病理分析。
各组动物存活情况见表5和图1,可见正常对照组和假手术对照组无动物死亡,存活率为100%,模型对照组存活率为37.5%,三个给药组均可以使得模型动物的存活率提高,且对存活率的改善与肽12的给药剂量具有相关性,其中肽12给药剂量1.25mg/kg可使得存活率得到明显的提升,存活率为66.7%,其存活率与对照组的比值为1.78。同时给药组存活动物的精神状态和活动状态显著优于对照组,对存活动物解剖进行大体观察,结果显示,给药组动物胰腺的水肿和液化、胃肠梗阻、腹水量、胆管阻塞、肺淤血和皂化斑等都有不同程度的改善。
表5各组动物存活情况
模型对照组与正常组和假手术组相比,血淀粉酶和脂肪酶水平显著升高,肽12与模型对照组相比,可使得血淀粉酶和脂肪酶水平降低(如见图2和图3)。
胰腺的损伤程度通过对胰腺制备HE切片,利用Schmidt方法对胰腺的水肿、炎症、出血和坏死等各个方面的病理改变进行评分,具体评分标准如下表6所示,胰腺总损伤为以上四项的加和。
表6.胰腺组织病理学评分标准
病理评分结果显示在表7和图4~图8中。
表7.病理改变评分结果
由图4~图8可见,肽12给药可以剂量相关性的降低牛黄胆酸钠对胰腺造成的病理损伤改变。
实施例2肽12对蛙皮素诱导胰腺炎模型的治疗效果
雄性BALB/c小鼠,6-8周龄,适应性喂养7天以上,禁食过夜后,随机选择10只动物作为正常对照组,剩余动物以50μg/kg蛙皮素腹腔注射,每隔1小时注射一次,共注射10次,制备急性胰腺炎模型,并随机分为模型对照组、肽12的0.025、0.25、2.5和25mg/kg给药组,每组10只,于第4次给予蛙皮素之前5分钟给予相应剂量的肽12或生理盐水。
于第10次注射蛙皮素后1小时结束实验,采集血液进行血淀粉酶和脂肪酶水平的测定,采集胰腺称重并固定于10%福尔马林固定液留待进行后续病理分析。
胰腺系数的计算采用胰腺重/体重,该结果反应了胰腺水肿的情况。实验统计结果显示在图9中,其中:###:与正常对照组相比P<0.001;**:与模型对照组相比P<0.01;***:与模型对照组相比P<0.001。从图9可以看出,模型组胰腺系数较正常对照组显著升高,肽12给药组0.025、0.25和2.5mg/kg三个剂量下,可显著降低胰腺系数,且具有剂量依赖关系。如图10和图11所示,模型对照组与正常组相比,血淀粉酶和脂肪酶水平显著升高,肽12与模型对照组相比,0.025、0.25、2.5和25mg/kg四个给药剂量下,均可使得血淀粉酶和脂肪酶显著降低。需要说明的是,在图10中,###:与正常对照组相比P<0.001;***:与模型对照组相比P<0.001;在图11中,###:与正常对照组相比P<0.001;***:与模型对照组相比P<0.001。
胰腺的损伤程度通过对胰腺制备HE切片,按照上述胰腺组织病理学评分标准,利用Schmidt方法对胰腺的水肿、炎症、出血和坏死等各个方面的病理改变进行评分。
表8.病理改变评分结果
病理评分结果显示,蛙皮素诱导的胰腺炎模型中并未见明显出血和坏死,水肿和炎症的评分情况如图12~图13所示。需要说明的是,在图12中,###:与正常对照组相比P<0.001;在图13中,###:与正常对照组相比P<0.001;*:与模型对照组相比P<0.05;**:与模型对照组相比P<0.01。从图12~图13可见,模型组与正常对照组相比,有明显的水肿和炎症损伤,肽12给药可降低蛙皮素对胰腺造成的水肿和炎症等病理损伤改变。
本发明已经根据一些具体的实施方案进行了描述。它们仅打算用于举例说明,不应以任何方式视为限制。因此,应理解可对其进行修改,此类修改在本发明和所附权利要求的范围内。另外,本文提及的所有专利、专利申请、论文和教科书均通过引用而结合至本文中。
Claims (2)
1.肽12在制备用于治疗急性胰腺炎的药物中的用途,其中肽12的氨基酸序列为Ac-IGLHDPSHGTLPAGS-OH;
所述肽12的给药剂量为0.025mg/kg/天~2.5mg/kg/天;
所述药物的唯一有效成分为所述肽12。
2.肽12在制备用于降低急性胰腺炎患者血液淀粉酶和脂肪酶水平的药物中的用途,其中肽12的氨基酸序列为Ac-IGLHDPSHGTLPAGS-OH;
所述肽12的给药剂量为0.025mg/kg/天~2.5mg/kg/天;
所述药物的唯一有效成分为所述肽12。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2017/084013 WO2018205233A1 (zh) | 2017-05-11 | 2017-05-11 | 多肽化合物在治疗急性胰腺炎中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110958885A CN110958885A (zh) | 2020-04-03 |
CN110958885B true CN110958885B (zh) | 2024-03-12 |
Family
ID=64104214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201780090649.9A Active CN110958885B (zh) | 2017-05-11 | 2017-05-11 | 多肽化合物在治疗急性胰腺炎中的应用 |
Country Status (8)
Country | Link |
---|---|
US (2) | US10772929B2 (zh) |
EP (1) | EP3639840A4 (zh) |
JP (1) | JP7169673B2 (zh) |
CN (1) | CN110958885B (zh) |
AU (1) | AU2017414006B2 (zh) |
BR (1) | BR112019023511A2 (zh) |
CA (1) | CA3063183A1 (zh) |
WO (1) | WO2018205233A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023143446A1 (en) * | 2022-01-25 | 2023-08-03 | Shenzhen Hightide Biopharmaceutical Ltd. | Compositions and methods for treating cytokine storm |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104045703A (zh) * | 2013-03-15 | 2014-09-17 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
CN104045702A (zh) * | 2013-03-15 | 2014-09-17 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
CN104045698A (zh) * | 2013-03-15 | 2014-09-17 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
WO2014139472A1 (en) * | 2013-03-15 | 2014-09-18 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
CN104650211A (zh) * | 2013-03-15 | 2015-05-27 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐、药物组合物及其应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6824822B2 (en) | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
US20090142338A1 (en) * | 2005-03-04 | 2009-06-04 | Curedm, Inc. | Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions |
JP5693817B2 (ja) | 2005-08-19 | 2015-04-01 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | 糖尿病の治療法および体重の減少法 |
US8785400B2 (en) * | 2006-11-22 | 2014-07-22 | Curedm Group Holdings, Llc | Methods and compositions relating to islet cell neogenesis |
SI2193142T1 (sl) | 2007-08-30 | 2015-05-29 | Curedm Group Holdings, Llc | Sestavek in postopek za uporabo proislet peptidov in analogov le-teh |
-
2017
- 2017-05-11 EP EP17909453.7A patent/EP3639840A4/en active Pending
- 2017-05-11 BR BR112019023511A patent/BR112019023511A2/pt unknown
- 2017-05-11 CN CN201780090649.9A patent/CN110958885B/zh active Active
- 2017-05-11 JP JP2019562654A patent/JP7169673B2/ja active Active
- 2017-05-11 WO PCT/CN2017/084013 patent/WO2018205233A1/zh unknown
- 2017-05-11 CA CA3063183A patent/CA3063183A1/en active Pending
- 2017-05-11 US US16/094,881 patent/US10772929B2/en active Active
- 2017-05-11 AU AU2017414006A patent/AU2017414006B2/en active Active
-
2020
- 2020-09-03 US US17/011,052 patent/US11534477B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104045703A (zh) * | 2013-03-15 | 2014-09-17 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
CN104045702A (zh) * | 2013-03-15 | 2014-09-17 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
CN104045698A (zh) * | 2013-03-15 | 2014-09-17 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
WO2014139472A1 (en) * | 2013-03-15 | 2014-09-18 | Shenzhen Hightide Biopharmaceutical, Ltd. | Compositions and methods of using islet neogenesis peptides and analogs thereof |
CN104650211A (zh) * | 2013-03-15 | 2015-05-27 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐、药物组合物及其应用 |
Non-Patent Citations (1)
Title |
---|
池肇春 等.《实用临床胃肠病学》.北京:军事医学科学出版社,2015,(第2015年4月第2版版),第1362-1364、1368、1370、1373页. * |
Also Published As
Publication number | Publication date |
---|---|
EP3639840A4 (en) | 2020-12-23 |
US10772929B2 (en) | 2020-09-15 |
JP7169673B2 (ja) | 2022-11-11 |
BR112019023511A2 (pt) | 2020-05-19 |
US20190216883A1 (en) | 2019-07-18 |
WO2018205233A1 (zh) | 2018-11-15 |
US20210100871A1 (en) | 2021-04-08 |
US11534477B2 (en) | 2022-12-27 |
AU2017414006A1 (en) | 2019-12-05 |
EP3639840A1 (en) | 2020-04-22 |
CN110958885A (zh) | 2020-04-03 |
CA3063183A1 (en) | 2019-12-03 |
JP2020519653A (ja) | 2020-07-02 |
AU2017414006B2 (en) | 2023-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210378984A1 (en) | Reduction of adipose tissue | |
ES2340939T3 (es) | Utilizacioin del treprostinil para tratar las ulceras de pie diabeticas neuropaticas. | |
WO2008040260A1 (es) | Uso del factor de crecimiento epidérmico para la restauración morfofuncional de nervios periféricos en la neuropatía diabética | |
BR112020019347A2 (pt) | composições farmacêuticas para inibição de citocinas inflamatórias | |
US11147786B2 (en) | Methods of treating chronic dry eye disease using C16:1n7-palmitoleate and derivatives thereof | |
CN110958885B (zh) | 多肽化合物在治疗急性胰腺炎中的应用 | |
US9873724B2 (en) | Pro-angiogenic peptides and peptide conjugates | |
US9107930B2 (en) | Method for treating unwanted localized fat deposits | |
JP2009534360A (ja) | アルファ−ケトグルタレートを含む組成物およびその筋性能を調節するための使用 | |
US20170209401A1 (en) | A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation | |
US20100143321A1 (en) | Therapeutic composition for interstitual pneumonia | |
JP2021502952A (ja) | 間質性膀胱炎の処置方法 | |
ES2332390T3 (es) | Composicion farmaceutica cerebroespinal y vascular y proceso para prepararla. | |
US11446264B2 (en) | Memory manipulation via modification of protein kinase C zeta activity | |
WO2021142737A1 (en) | Compositions and methods for treating non-alcoholic steatohepatitis (nash) | |
WO2023215323A1 (en) | Intranasal baclofen | |
EP4294520A2 (en) | Protein-based therapies for ocular conditions | |
JP2007531702A (ja) | 放射線防護におけるg53135−05(fgf−20)の治療的使用 | |
US20140235545A1 (en) | The use of HCV immunogenic peptide or a derivative thereof in the prevention or treatment of arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |